New York, February 10, 2026, 05:11 EST — Premarket
- Abpro Holdings surged roughly 94% ahead of the bell, following a fresh ownership filing.
- Goldman Sachs entities owned 6.8% of Abpro’s common stock at the end of December, according to a Schedule 13G filing.
- Traders are eyeing if the move sticks through the cash open, following a burst of after-hours action.
Abpro Holdings, Inc shares soared roughly 94% to $2.95 early Tuesday, premarket, after a regulatory filing revealed a sizable new investor in the microcap biotech. 1
The filing revealed The Goldman Sachs Group and Goldman Sachs & Co. LLC held 196,537 shares—6.8% of Abpro’s common stock—as of Dec. 31. Goldman filed a Schedule 13G, the short-form disclosure investors use when their stake tops 5% but remains passive. According to the document, the shares are kept in the “ordinary course of business,” with no intent to sway company control. 2
Abpro shares closed at $1.52 on Monday, a 1.33% gain, with volume landing near 2.77 million shares, market data show. 3
SEC records indicate the Schedule 13G came in on Feb. 9, with acceptance logged at 4:07 p.m. ET. 4
The action rolled right into after-hours, with Abpro changing hands at $2.8598 as of Monday evening—an 88% jump. Roughly 14 million shares traded after the bell, according to MarketWatch data. 5
Massachusetts biotech Abpro is working on multispecific antibody therapies. Last month, the company and Celltrion (South Korea) announced the U.S. FDA had greenlit their investigational new drug application for ABP-102/CT-P72. They expect to kick off a Phase 1 trial in the first half of 2026. 6
Abpro shares swung from $2.88 to $2.95 during Tuesday’s premarket action—those quick gaps, typical for thinly traded early sessions. 7
But a 13G only shows a moment in time. The filing is based on holdings as of Dec. 31—it doesn’t specify when the shares were picked up or if that stake still holds. In small-cap names, big premarket swings like these can unravel fast after the bell, as trading volume picks up.
